Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DeMarini

Showing results (291-300 of 314) with videos related to

Pageof 32
Sort By:
Scientific Reports|January 16, 2019
High-Throughput Video Processing of Heart Rate Responses in Multiple Wild-type Embryonic Zebrafish per Imaging FieldW Kyle Martin, Alan H Tennant, Rory B Conolly, et al.
Eclinicalmedicine|September 4, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 studyMarek Trněný, Abraham Avigdor, Matthew S McKinney, et al.
Environmental Science & Technology|July 10, 2019
Predictive Analysis Using Chemical-Gene Interaction Networks Consistent with Observed Endocrine Activity and Mutagenicity of U.S. StreamsJason P Berninger, David M DeMarini, Sarah H Warren, et al.
Carcinogenesis|May 1, 1997
Urinary mutagenicity as a biomarker in workers exposed to benzidine: correlation with urinary metabolites and urothelial DNA adductsD M DeMarini, L R Brooks, V K Bhatnagar, et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis|February 24, 2020
Revisiting the bacterial mutagenicity assays: Report by a workgroup of the International Workshops on Genotoxicity Testing (IWGT)Rita Schoeny, Kevin P Cross, David M DeMarini, et al.
Eclinicalmedicine|August 21, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 studyPier Luigi Zinzani, Marek Trněný, Vincent Ribrag, et al.
Environmental Health Perspectives|November 25, 2015
Key Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of CarcinogenesisMartyn T Smith, Kathryn Z Guyton, Catherine F Gibbons, et al.
The Lancet. Oncology|July 19, 2012
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialJeffrey R Infante, Leslie A Fecher, Gerald S Falchook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorKevin B Kim, Richard Kefford, Anna C Pavlick, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaDirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.
Pageof 32

Showing results (291-300 of 314) with videos related to

Sort By:
Pageof 32
Scientific Reports|January 16, 2019
High-Throughput Video Processing of Heart Rate Responses in Multiple Wild-type Embryonic Zebrafish per Imaging FieldW Kyle Martin, Alan H Tennant, Rory B Conolly, et al.
Eclinicalmedicine|September 4, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 studyMarek Trněný, Abraham Avigdor, Matthew S McKinney, et al.
Environmental Science & Technology|July 10, 2019
Predictive Analysis Using Chemical-Gene Interaction Networks Consistent with Observed Endocrine Activity and Mutagenicity of U.S. StreamsJason P Berninger, David M DeMarini, Sarah H Warren, et al.
Carcinogenesis|May 1, 1997
Urinary mutagenicity as a biomarker in workers exposed to benzidine: correlation with urinary metabolites and urothelial DNA adductsD M DeMarini, L R Brooks, V K Bhatnagar, et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis|February 24, 2020
Revisiting the bacterial mutagenicity assays: Report by a workgroup of the International Workshops on Genotoxicity Testing (IWGT)Rita Schoeny, Kevin P Cross, David M DeMarini, et al.
Eclinicalmedicine|August 21, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 studyPier Luigi Zinzani, Marek Trněný, Vincent Ribrag, et al.
Environmental Health Perspectives|November 25, 2015
Key Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of CarcinogenesisMartyn T Smith, Kathryn Z Guyton, Catherine F Gibbons, et al.
The Lancet. Oncology|July 19, 2012
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialJeffrey R Infante, Leslie A Fecher, Gerald S Falchook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorKevin B Kim, Richard Kefford, Anna C Pavlick, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaDirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.
Pageof 32